Autolus Therapeutics plc (AUTL)
Autolus Therapeutics develops and makes T cell therapies for cancer and autoimmune diseases, and sells AUCATZYL for leukemia. It last closed at $1.42 on Nov 2. AUTL reports earnings on Tue, Nov 10, 2026.
Key Stats
Last 12 monthsNot reported for this period.
From AUTL's SEC filings, latest 10-Q for the period ending Jun 30, 2026 (filed Aug 11). Last 12 months adds up the four latest quarters.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 3 | HC Wainwright & Co. | Reiterated | Buy | $10 |
Technical Analysis
The stock is 15% below its 20 day and 33% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 32), near oversold. The nearest support is the swing low (Jul 28) at $1.41, and the nearest resistance the Pivot at $1.46.
| RSI (14) | 31.87 | Weak, oversold below 30 | Neutral |
| MACD | -0.10 | Below its signal line | Bearish |
| Stochastic | 16.8 | Near the bottom of its range | Oversold |
| ADX (14) | 27.3 | Trending down | |
| Williams %R | -90.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -151.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −10.7% | Change over 10 sessions | Bearish |
| ATR (14) | $0.10 | Typical daily range, 7.1% of price |
| RSI (14) | 40.07 | Middle of its range | Neutral |
| MACD | -0.02 | Below its signal line | Bearish |
| Stochastic | 8.6 | Near the bottom of its range | Oversold |
| ADX (14) | 15.2 | No clear trend | |
| Williams %R | -97.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -91.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −39.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.24 | Typical daily range, 16.6% of price |
What happened before
See how AUTL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How AUTL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.
Whale Options Flow
90DNo whale options trades in AUTL in the last 90 days.
AUTL Institutional Ownership
Hedge fund holdings →| # | Fund | Shares | Of company | Value | Change | |
|---|---|---|---|---|---|---|
| 1 | Mak Capital One LLC | 33.6M | 12.63% | $53.8M | 0 | No change |
| 2 | Blackstone Inc. | 20.5M | 7.70% | $32.8M | 0 | No change |
| 3 | Syncona Portfolio Ltd | 16.6M | 6.25% | $26.6M | 0 | No change |
| 4 | Armistice Capital, LLC | 15M | 5.64% | $24.0M | −800K | Trimmed |
| 5 | Tetragon Partners GP Ltd | 9.5M | 3.57% | $15.2M | 0 | No change |
| 6 | Schroder Investment Management Group | 7.8M | 2.94% | $12.9M | −1.7M | Trimmed |
| 7 | Frazier Life Sciences Management, L.P. | 4.4M | 1.67% | $7.1M | 0 | No change |
| 8 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3.4M | 1.26% | $5.4M | 0 | No change |
| 9 | Laurion Capital Management LP | 3.3M | 1.25% | $5.3M | 0 | No change |
| 10 | Renaissance Technologies LLC | 2M | 0.75% | $3.2M | −315K | Trimmed |
| 11 | Bank of America Corp /de/ | 1.6M | 0.60% | $2.6M | −240K | Trimmed |
| 12 | BlackRock, Inc. | 1.6M | 0.60% | $2.6M | +123K | Added |
| 13 | UBS Group AG | 1.5M | 0.57% | $2.4M | +211K | Added |
| 14 | Morgan Stanley | 1.3M | 0.47% | $2.0M | +319K | Added |
| 15 | Millennium Management LLC | 1.2M | 0.46% | $2.0M | +1M | Added |
| 16 | Cetera Investment Advisers | 1.2M | 0.43% | $1.9M | +28K | Added |
| 17 | Balyasny Asset Management L.P. | 973K | 0.37% | $1.6M | +1,057 | Added |
| 18 | Jpmorgan Chase & Co | 913K | 0.34% | $1.5M | −22K | Trimmed |
| 19 | Alphabet Inc. | 698K | 0.26% | $1.1M | 0 | No change |
| 20 | Citadel Advisors LLC | 696K | 0.26% | $1.1M | +236K | Added |
| 21 | Hennion & Walsh Asset Management, Inc. | 451K | 0.17% | $722K | +11K | Added |
| 22 | Privium Fund Management B.V. | 363K | 0.14% | $581K | 0 | No change |
| 23 | EDENTREE ASSET MANAGEMENT Ltd | 300K | 0.11% | $477K | 0 | No change |
| 24 | Jane Street Group, LLC | 300K | 0.11% | $480K | +54K | Added |
| 25 | XTX Topco Ltd | 287K | 0.11% | $460K | +231K | Added |
- Millennium Management LLC+1M sh$1.6M
- Morgan Stanley+319K sh$510K
- Citadel Advisors LLC+236K sh$378K
- XTX Topco Ltd+231K sh$370K
- UBS Group AG+211K sh$338K
- BlackRock, Inc.+123K sh$196K
- Schroder Investment Management Group−1.7M sh−$2.7M
- Armistice Capital, LLC−800K sh−$1.3M
- Marex Group Ltd−525K sh−$840K
- Point72 Asset Management, L.P.−356K sh−$569K
- Renaissance Technologies LLC−315K sh−$504K
- Bank of America Corp /de/−240K sh−$383K
- Hennion & Walsh Asset Management, Inc.Trimmed−32K shOct 13
- Vise Technologies, Inc.New+18K shOct 29
- Quantum Financial Partners LLCSold out−19K shOct 19
- SmartHarvest Portfolios, LLCTrimmed−15K shOct 26
- Simplicity Wealth,LLCNew+11K shOct 23
- Caitong International Asset Management Co., LtdAdded+9,944 shOct 29
- Meridian Financial Partners LLCNew+10K shOct 23
- China Universal Asset Management Co., Ltd.Added+4,677 shOct 28
From SEC Form 13F filings by funds managing over $100 million, as of Jun 30, 2026. Changes compare each fund with its own Q1 2026 filing. "Held by funds" adds up the shares every 13F filer reported, over shares outstanding. Filings come up to 45 days after the quarter ends. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AUTL is in one of them and how their past AUTL trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AUTL in an article yet. Here's the latest on the wider market.
About Autolus Therapeutics
Autolus Therapeutics is a biopharmaceutical company based in London, United Kingdom. It develops and manufactures cell therapies that reprogram a patient's own T cells so they can recognize and attack target cells. Its main product, AUCATZYL, is approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia in the United States and the United Kingdom. The company is also testing its therapy in other cancers and in autoimmune diseases such as lupus and multiple sclerosis.
- Headquarters
- London, United Kingdom